Read Dr. Amanda Yaworski’s Early Career Blog
Read the latest early career blog post, from NMD4C member Dr. Amanda Yaworski.
Dr. Amanda Yaworski completed an undergraduate degree at Acadia University in Psychology and Neurosciences, followed by medical school at McMaster University and residency in Pediatric Neurology at the University of Alberta. Dr. Yaworski will be attending Stanford University this summer to complete a fellowship in neurophysiology and neuromuscular medicine.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.